A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  title={A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)},
  author={David Schultz},
  journal={The Lancet},
  • D. Schultz
  • Published 16 November 1996
  • Medicine, Biology
  • The Lancet

Benefit of ADP Receptor Antagonists in Atherothrombotic Patients: New Evidence

A potential clinically useful advantage of clopidogrel is its low propensity for adverse interaction with angiotensin-converting enzyme (ACE) inhibitors, contrary to what may be seen with aspirin, as observed in a post-hoc CAPRIE analysis.

Results of the CAPRIE trial: efficacy and safety of clopidogrel

Results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis.

Clopidogrel – Confounding or Confirming Our Concept of How to Treat Acute Coronary Syndromes?

Clinical trials generally suggest that patients with atherosclerotic vascular disease are more effectively managed with long-term clopidogrel than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction or vascular death, and the combination of clopIDogrel and aspirin is safer when compared to ticlopidine and aspirin following percutaneous coronary intervention.

The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study

The available data support the use of clopidogrel as a clinically efficient and cost-effective option for secondary prevention of atherothrombotic disease, particularly in high-risk patients.

Aspirin in Neurology

Among more than 23000 patients, antiplatelet therapy compared with placebo or untreated control continued for a mean of 29 months was associated with a 22% reduction in the odds of recurrent ischemic stroke, myocardial infarction (MI), or vascular death.

A Randomised Controlled Trial of Triple Antiplatelet Therapy (Aspirin, Clopidogrel and Dipyridamole) in the Secondary Prevention of Stroke: Safety, Tolerability and Feasibility

Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations, however, the patients had a low risk of recurrence and future trials should focus on short term therapy in high risk patients characterised by a very recent event or failure of dual antiplatelets therapy.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.

Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data

MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopIDogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden

Clopidogrel appears to be associated with costs per QALY that range from intermediate in the total CAPRIE population to low in high-risk atherosclerotic patients, when considering the cost-effectiveness categorization as proposed by the Swedish National Board of Health and Welfare.